359 related articles for article (PubMed ID: 33193105)
1. Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH.
Jadhav K; Cohen TS
Front Endocrinol (Lausanne); 2020; 11():592157. PubMed ID: 33193105
[TBL] [Abstract][Full Text] [Related]
2. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
[TBL] [Abstract][Full Text] [Related]
3. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
4. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
[TBL] [Abstract][Full Text] [Related]
5. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol.
Rahman K; Desai C; Iyer SS; Thorn NE; Kumar P; Liu Y; Smith T; Neish AS; Li H; Tan S; Wu P; Liu X; Yu Y; Farris AB; Nusrat A; Parkos CA; Anania FA
Gastroenterology; 2016 Oct; 151(4):733-746.e12. PubMed ID: 27342212
[TBL] [Abstract][Full Text] [Related]
6. Current Research on the Pathogenesis of NAFLD/NASH and the Gut-Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome.
Kobayashi T; Iwaki M; Nakajima A; Nogami A; Yoneda M
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232990
[TBL] [Abstract][Full Text] [Related]
7. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
Boursier J; Mueller O; Barret M; Machado M; Fizanne L; Araujo-Perez F; Guy CD; Seed PC; Rawls JF; David LA; Hunault G; Oberti F; Calès P; Diehl AM
Hepatology; 2016 Mar; 63(3):764-75. PubMed ID: 26600078
[TBL] [Abstract][Full Text] [Related]
8. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
Safari Z; Gérard P
Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
[TBL] [Abstract][Full Text] [Related]
9. [Microbiome & NASH - partners in crime driving progression of fatty liver disease].
Wree A; Geisler LJ; Tacke F
Z Gastroenterol; 2019 Jul; 57(7):871-882. PubMed ID: 31288283
[TBL] [Abstract][Full Text] [Related]
10. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target.
Kessoku T; Kobayashi T; Tanaka K; Yamamoto A; Takahashi K; Iwaki M; Ozaki A; Kasai Y; Nogami A; Honda Y; Ogawa Y; Kato S; Imajo K; Higurashi T; Hosono K; Yoneda M; Usuda H; Wada K; Saito S; Nakajima A
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360923
[TBL] [Abstract][Full Text] [Related]
11. Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales.
Carter JK; Bhattacharya D; Borgerding JN; Fiel MI; Faith JJ; Friedman SL
PLoS One; 2021; 16(1):e0244763. PubMed ID: 33395434
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-17 Weakens the NAFLD/NASH Process by Facilitating Intestinal Barrier Restoration Depending on the Gut Microbiota.
He S; Cui S; Song W; Jiang Y; Chen H; Liao D; Lu X; Li J; Chen X; Peng L
mBio; 2022 Apr; 13(2):e0368821. PubMed ID: 35266816
[TBL] [Abstract][Full Text] [Related]
13. Diet and gut microbiome in fatty liver and its associated liver cancer.
Pan Y; Zhang X
J Gastroenterol Hepatol; 2022 Jan; 37(1):7-14. PubMed ID: 34664301
[TBL] [Abstract][Full Text] [Related]
14. Intestinal microbiota and nonalcoholic steatohepatitis.
Brandl K; Schnabl B
Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
[TBL] [Abstract][Full Text] [Related]
15. Blocking integrin α
Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
[TBL] [Abstract][Full Text] [Related]
16. Gut inflammation exacerbates hepatic injury in the high-fat diet induced NAFLD mouse: Attention to the gut-vascular barrier dysfunction.
Cheng C; Tan J; Qian W; Zhang L; Hou X
Life Sci; 2018 Sep; 209():157-166. PubMed ID: 30096384
[TBL] [Abstract][Full Text] [Related]
17. Interactions between the cecal microbiota and non-alcoholic steatohepatitis using laying hens as the model.
Hamid H; Zhang JY; Li WX; Liu C; Li ML; Zhao LH; Ji C; Ma QG
Poult Sci; 2019 Jun; 98(6):2509-2521. PubMed ID: 30690636
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
20. [Gut microbiota and nonalcoholic steatohepatitis].
Kessoku T; Imajo K; Kobayashi T; Honda Y; Ogawa Y; Yoneda M; Saito S; Nakajima A
Nihon Yakurigaku Zasshi; 2018; 152(4):187-193. PubMed ID: 30298840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
